Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GRN | P28799 | 1/20 | 0.30 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19508022 | 0.80 | CA12 (0.39) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL18007685 | 0.77 | LMNA (0.49) | MEN1KMT2AKDM4EALDH1A1LMNA | |
| SCHEMBL28199954 | 0.76 | LMNA (0.32) | MEN1KMT2AKDM4EGRNSORT1 | |
| SCHEMBL23329032 | 0.73 | TAS2R14 (0.46) | LMNAMAPT | |
| SCHEMBL18007631 | 0.73 | KDM4E (0.31) | KDM4EGRNSORT1 | |
| SCHEMBL20885970 | 0.68 | RECQL (0.33) | KMT2A | |
| SCHEMBL18029742 | 0.68 | BAZ2B (0.40) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL22019982 | 0.68 | GAA (0.35) | MEN1KMT2AKDM4EALDH1A1MAPT | |
| SCHEMBL29284965 | 0.65 | — | — | |
| SCHEMBL22012923 | 0.65 | MAPT (0.35) | KDM4EALDH1A1LMNAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | MEN1 2600/4885KMT2A 2978/4885KDM4E 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.